Evaluating the neuroprotection, neurotoxicity and hemolytic activity of Fraternine-10 and Octovespin in in vitro assays

- 320882
Abstract
Favorite this paper
How to cite this paper?
Abstract

Alzheimer’s disease (AD) and Parkinson’s disease (PD) are the two most prevalent neurodegenerative diseases, with no current cure or effective treatment that could slow down their progression. Leading the search for new therapeutic alternatives, peptides have become a common theme for many scientists, due to their unique properties, with many of them showing promising efficacy.

Fraternine-10 and Octovespin are two examples of bioinspired peptides that showed promising results in AD and PD animal models but their mechanism of action is still under study. In vitro research plays a crucial role in the early stages of drug development, allowing for a safe and precise way to evaluate a compound's therapeutic potential, thus, for Fratenine-10 and Octovespin, in vitro studies could provide a controlled environment to assess their pathophysiological relevance on cellular models that replicate neurodegeneration scenarios, which is the aim of this study.

Therefore, to evaluate Octovespin and Fraternine-10 neuroprotection property, human neuroblastoma (SHSY-5Y) was used and 6-OHDA was added to induce neurotoxicity, followed by measurements of DCFDA and Resazurin fluorescence, to evaluate ROS production and cell viability, respectively. To evaluate the peptide's neurotoxicity, human neuroblastoma (SHSY-5Y) was incubated with Fraternine and Octovespin at similar doses. At last the hemolytic activity of both peptides was evaluated in a 3% suspension of erythrocytes from mice blood, analyzed using spectrophotometry.

When peptides were added in neuroblastoma cells exposed to 6-OHDA there was no change on the resazurin fluorescence, implying that Fraternine-10 and Octovespin were not able to prevent 6-OHDA neurotoxicity. However, when peptides were incubated with neuroblastoma cells alone, a decreased level of fluorescence was observed at the DCFDA trials without changes in resazurin. Hemolysis assays revealed that none of the peptide doses caused hemolysis.

In conclusion, the results from the neurotoxicity assay using resazurin showed that the peptides at the tested doses were not neuroprotective, but had an antioxidant activity. Moreover, the hemolytic assay showed that both peptides, in the tested doses, were not hemolytic for the erythrocytes from mice. Taken together, more studies and optimization of those peptides are necessary in order to elucidate better their effect.

Share your ideas or questions with the authors!

Did you know that the greatest stimulus in scientific and cultural development is curiosity? Leave your questions or suggestions to the author!

Sign in to interact

Have a question or suggestion? Share your feedback with the authors!

Institutions
  • 1 Universidade de Brasília | (University of Brasília)
  • 2 University of Brasília
  • 3 University of Brasilia
Track
  • Peptides and neurological disorders
Keywords
Venom peptides
Toxins
Alzheimer’s disease
Parkinson’s disease